Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Keros Therapeutics (KROS) over the last 4 years, with Q3 2025 value amounting to -$1.4 million.

  • Keros Therapeutics' Tax Provisions changed N/A to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year change of. This contributed to the annual value of $300000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Keros Therapeutics reported Tax Provisions of -$1.4 million as of Q3 2025.
  • In the past 5 years, Keros Therapeutics' Tax Provisions registered a high of $10.0 million during Q1 2025, and its lowest value of -$2.2 million during Q2 2025.
  • Over the past 3 years, Keros Therapeutics' median Tax Provisions value was $50000.0 (recorded in 2021), while the average stood at $1.2 million.
  • Examining YoY changes over the last 5 years, Keros Therapeutics' Tax Provisions showed a top increase of 12906.98% in 2021 and a maximum decrease of 12906.98% in 2021.
  • Quarter analysis of 3 years shows Keros Therapeutics' Tax Provisions stood at $2.0 million in 2021, then crashed by 84.99% to $300000.0 in 2024, then crashed by 574.67% to -$1.4 million in 2025.
  • Its Tax Provisions stands at -$1.4 million for Q3 2025, versus -$2.2 million for Q2 2025 and $10.0 million for Q1 2025.